Cargando…

Cytokine and Chemokine Profile in Patients with Multiple Myeloma Treated with Bortezomib

The aim of the study was to determine the levels of selected cytokines and chemokines in the serum of multiple myeloma (MM) patients treated with bortezomib-based regimens. A total of 71 MM patients were examined: 41 with primary refractory disease (17) or early relapse (28), and 30 who were bortezo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Robak, Paweł, Węgłowska, Edyta, Dróżdż, Izabela, Mikulski, Damian, Jarych, Dariusz, Ferlińska, Magdalena, Wawrzyniak, Ewa, Misiewicz, Małgorzata, Smolewski, Piotr, Fendler, Wojciech, Szemraj, Janusz, Robak, Tadeusz
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7294367/ https://www.ncbi.nlm.nih.gov/pubmed/32587468 http://dx.doi.org/10.1155/2020/1835836

Ejemplares similares

The Value of Serum MicroRNA Expression Signature in Predicting Refractoriness to Bortezomib-Based Therapy in Multiple Myeloma Patients
por: Robak, Paweł, et al.
Publicado: (2020)

The Prognostic Value of Whole-Blood PSMB5, CXCR4, POMP, and RPL5 mRNA Expression in Patients with Multiple Myeloma Treated with Bortezomib
por: Robak, Pawel, et al.
Publicado: (2021)

Pretreatment Serum Levels of IL-1 Receptor Antagonist and IL-4 Are Predictors of Overall Survival in Multiple Myeloma Patients Treated with Bortezomib
por: Mikulski, Damian, et al.
Publicado: (2021)

The Relationship between Serum miRNAs and Early Mortality in Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Puła, Anna, et al.
Publicado: (2023)

Prognostic Value of Resistance Proteins in Plasma Cells from Multiple Myeloma Patients Treated with Bortezomib-Based Regimens
por: Robak, Paweł, et al.
Publicado: (2021)

P868: A CIRCULATING SERUM MIRNAS-BASED MODEL TO PREDICT EARLY MORTALITY IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-BASED REGIMENS.
por: Puła, A., et al.
Publicado: (2022)

The Significance of mRNA in the Biology of Multiple Myeloma and Its Clinical Implications
por: Puła, Anna, et al.
Publicado: (2021)

Bortezomib for the Treatment of Hematologic Malignancies: 15 Years Later
por: Robak, Pawel, et al.
Publicado: (2019)

Risk Factors of Infection in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide and Dexamethasone (Rd) Regimen: Real-Life Results of a Large Single-Center Study
por: Mikulski, Damian, et al.
Publicado: (2022)

High serum miR-223-3p expression level predicts complete response and prolonged overall survival in multiple myeloma patients undergoing autologous hematopoietic stem cell transplantation
por: Mikulski, Damian, et al.
Publicado: (2023)

Expression of Toll-Like Receptors 3, 7, and 9 in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus
por: Klonowska-Szymczyk, Agnieszka, et al.
Publicado: (2014)

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions
por: Robak, Tadeusz, et al.
Publicado: (2022)

Bruton’s Kinase Inhibitors for the Treatment of Immunological Diseases: Current Status and Perspectives
por: Robak, Ewa, et al.
Publicado: (2022)

Clinical significance of circulating dendritic cells in patients with systemic lupus erythematosus.
por: Robak, E, et al.
Publicado: (2004)

Leukemia Cutis—The Current View on Pathogenesis, Diagnosis, and Treatment
por: Robak, Ewa, et al.
Publicado: (2023)

High serum level of endostatin in multiple myeloma at diagnosis but not in the plateau phase after treatment.
por: Urbańska-Ryś, Halina, et al.
Publicado: (2003)

Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus.
por: Robak, Ewa, et al.
Publicado: (2003)

Skin changes in hairy cell leukemia
por: Robak, Ewa, et al.
Publicado: (2020)

Exhaled IL-8 in Systemic Lupus Erythematosus with and without Pulmonary Fibrosis
por: Nielepkowicz-Goździńska, Agnieszka, et al.
Publicado: (2014)

Current Status of Older and New Purine Nucleoside Analogues in the Treatment of Lymphoproliferative Diseases
por: Robak, Tadeusz, et al.
Publicado: (2009)

Measurable residual disease in hairy cell leukemia: Technical considerations and clinical significance
por: Robak, Tadeusz, et al.
Publicado: (2022)

The selected genetic polymorphisms of metalloproteinases MMP2, 7, 9 and MMP inhibitor TIMP2 in sarcoidosis
por: Piotrowski, Wojciech J., et al.
Publicado: (2011)

Circulating Total and Active Metalloproteinase-9 and Tissue Inhibitor of Metalloproteinases-1 in Patients with Systemic Lupus Erythomatosus
por: Robak, Ewa, et al.
Publicado: (2006)

Application of New Drugs in Chronic Lymphocytic Leukemia
por: Robak, Tadeusz
Publicado: (2010)

Book review: Safety of Biologics Therapy
por: Robak, Tadeusz
Publicado: (2017)

Toll-like receptors and their role in carcinogenesis and anti-tumor treatment
por: Wolska, Anna, et al.
Publicado: (2008)

Pro-Apoptotic Activity of New Honokiol/Triphenylmethane Analogues in B-Cell Lymphoid Malignancies
por: Mędra, Aleksandra, et al.
Publicado: (2016)

Hemostatic changes after 1 month of thalidomide and dexamethasone therapy in patients with multiple myeloma
por: Robak, Marta, et al.
Publicado: (2012)

Biotransformation of acetophenone and its halogen derivatives by Yarrowia lipolytica strains
por: Janeczko, Tomasz, et al.
Publicado: (2014)

Cardiac Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
por: Robak, Tadeusz, et al.
Publicado: (2022)

Bortezomib in the management of multiple myeloma
por: Laubach, Jacob P, et al.
Publicado: (2009)

Safety and Tolerability of Antibody-Drug Conjugates in Cancer
por: Wolska-Washer, Anna, et al.
Publicado: (2019)

Zanubrutinib for the treatment of lymphoid malignancies: Current status and future directions
por: Wolska-Washer, Anna, et al.
Publicado: (2023)

Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
por: Richardson, Paul G., et al.
Publicado: (2021)

Atypical Chronic Lymphocytic Leukemia—The Current Status
por: Robak, Tadeusz, et al.
Publicado: (2023)

PI3K Inhibitors for the Treatment of Chronic Lymphocytic Leukemia: Current Status and Future Perspectives
por: Hus, Iwona, et al.
Publicado: (2022)

Editorial: Novel targeted drugs for indolent lymphoid malignancies
por: Robak, Tadeusz, et al.
Publicado: (2023)

Bortezomib (Velcade™) in the Treatment of Multiple Myeloma
por: Field-Smith, Antonia, et al.
Publicado: (2006)

Identification and association of the single nucleotide polymorphisms, C−509T, C+466T and T+869C, of the TGF-β1 gene in patients with asthma and their influence on the mRNA expression level of TGF-β1
por: PANEK, MICHAŁ, et al.
Publicado: (2014)

Association of low ficolin-2 concentration in cord serum with respiratory distress syndrome in preterm newborns
por: Gajek, Gabriela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_70cckveltefi9bvkb2v1cokdbo